Found 9 articles for: "Ixekizumab"
Eruptive Lentiginosis Within Resolved Psoriasis Plaques: A Case Report and Systematic Review of the Literature
April 2026 | Volume 25 | Issue 4 | Original Article | 324 | Copyright © April 2026
Background: Many patients with psoriasis suffer from post-inflammatory pigmentary alteration (PIPA), which remains an unmet treatment need. Eruptive lentiginosis (EL) is a rare f...
Read MoreBenefits Over Five Years of Ixekizumab Treatment in Patients With Psoriasis Involving Challenging Body Areas
August 2024 | Volume 23 | Issue 8 | Original Article | 619 | Copyright © August 2024
Background: Psoriasis involving challenging body areas, such as the scalp, face, palmoplantar surfaces, or nails, can be challenging to treat and negatively affects patient outco...
Read MoreOutcomes for Psoriasis by Self-Identified Racial Groups in Ixekizumab Clinical Trials: A Pooled Analysis
February 2024 | Volume 23 | Issue 2 | Original Article | 17 | Copyright © February 2024
Background: Biologics have shown promising outcomes in psoriasis clinical trials. However, there is a paucity of data exploring the potential differences in outcomes between self...
Read MoreSubgroup Analyses by European Country-Specific Reimbursement Requirements Confirm Efficacy for Ixekizumab in Psoriasis
June 2022 | Volume 21 | Issue 6 | Original Article | 659 | Copyright © June 2022
Background: Biologic drugs are generally recommended for treating moderate-to-severe psoriasis. While eligibility criteria are primarily defined by clinical treatment guidelines, acce...
Read MoreLong-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study
April 2022 | Volume 21 | Issue 4 | Original Article | 399 | Copyright © April 2022
Background: There is a paucity of long-term real-world evidence comparing the effectiveness of ixekizumab (IXE) and adalimumab (ADA). We compared real-world treatment patterns of IXE-...
Read MoreAdjunctive Use of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Patients With Psoriasis Treated With Ixekizumab
March 2022 | Volume 21 | Issue 3 | Original Article | 235 | Copyright © March 2022
Objective: To examine the effectiveness and safety of adjunctive treatment with calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam in adult patients with chronic pla...
Read MoreEarly Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or Ustekinumab
February 2022 | Volume 21 | Issue 2 | Original Article | 122 | Copyright © February 2022
Background: The identification of early treatment factors that predict the long-term success of maintenance therapy for psoriasis may help optimize individual therapy.
O...
Read MoreEffect of Ixekizumab on Patient Reported Outcomes and Quality of Life in Patients With Moderate-to-Severe Plaque Psoriasis: 5-Year Results from the UNCOVER-1 and -2 Studies
April 2021 | Volume 20 | Issue 4 | Original Article | 394 | Copyright © April 2021
Objective: We describe patient-reported outcomes and quality of life through 5 years of treatment in patients with moderate-to-severe plaque Read More
Remission of Refractory PASH Syndrome Using Ixekizumab and Doxycycline
November 2020 | Volume 19 | Issue 11 | Editorials | 1124 | Copyright © November 2020
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.